Non-hormonal systemic medications and dry eye

Ocular Surface

Volumn 9, Issue 4, 2011, Pages 212-226

  Wong, John ^a   Lan, Wanwen ^b   Ong, Li Ming ^d   Tong, Louis ^b,c,d  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Anticholinergic agents; Antidepressants; Antihistamines; Antipsychotics; Anxiolytics; Chemically induced dry eye; Dry eye syndrome; Isotretinoin; Overactive bladder; Parkinson's disease

Indexed keywords

AGOMELATINE; ALPRAZOLAM; AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENAPRYZINE; BORNAPRINE; CARBIDOPA PLUS LEVODOPA; CETIRIZINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DECONGESTIVE AGENT; DEPRANIL; DESIPRAMINE; DOXEDEP; DOXEPIN; DULOXETINE; ESCITALOPRAM; FESOTERODINE; FLUOXETINE; FLUVOXAMINE MALEATE; HALOPERIDOL; IMIPRAMINE; LORATADINE; METIXENE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; ORPHENADRINE CITRATE; PAROXETINE; PRAMIPEXOLE; PROCYCLIDINE; PSEUDOEPHEDRINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SCOPOLAMINE; SERTRALINE; SULPIRIDE; TAZODAC; THIORIDAZINE; TIANEPTINE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AKATHISIA; AKINESIA; ANTICHOLINERGIC EFFECT; BINDING AFFINITY; BLURRED VISION; CONFUSION; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG STRUCTURE; DRY EYE; HUMAN; INTESTINE OBSTRUCTION; KERATITIS; KERATOMILEUSIS; NONHUMAN; OVERACTIVE BLADDER; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SWEATING; TREATMENT INDICATION; URINE RETENTION; XEROSTOMIA;

EID: 80755148733     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(11)70034-9     Document Type: Review

References (126)

1. Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care 2008;14(3 Suppl):S79-87 (Pubitemid 351656965)
2. Moss SE, Klein R, Klein BE. Incidence of dry eye in an older population. Arch Ophthalmol 2004;122:369-73 (Pubitemid 38314200)
3. Blomquist PH. Ocular complications of systemic medications. Am J Med Sci 2010;342:62-9
4. Moss SE, Klein R, Klein BE . Long-term incidence of dry eye in an older population. Optom Vis Sci 2008;85:668-74
5. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 2003;31:229-32 (Pubitemid 36833372)
6. (No authors listed). The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92
7. Bron AJ, Tiffany JM. The meibomian glands and tear film lipids. Structure, function, and control. Adv Exp Med Biol 1998;438:281-95
8. Katzung BG, Masters SB, Trevor AJ (eds). Basic and clinical pharmacology, 11th ed. New York, McGraw-Hill Medical, 2009
9. Creuzot-Garcher C. [Ocular dryness related to systemic medications]. J Fr Ophtalmol 2009;32:64-70. French
10. Pramanik T, Ghising R. Salivation induced better lacrimal gland function in dry eyes. Nepal Med Coll J 2009;11:258-60
11. Apostol S, Filip M, Dragne C, Filip A. Dry eye syndrome. Etiological and therapeutic aspects. Oftalmologia 2003;59:28-31
12. Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 2002;43:632-8 (Pubitemid 34184477)
13. Viau S, Maire MA, Pasquis B, et al. Time course of ocular surface and lacrimal gland changes in a new scopolamine-induced dry eye model. Graefes Arch Clin Exp Ophthalmol 2008;246:857-67
14. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol 2009;127:763-8
15. Moss SE, Klein R, Klein BE . Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000;118:1264-8
16. Celik L, Kaynak T, Ozerdem A, et al. Disappointment of patients on antidepressant therapy after excimer laser treatment. J Cataract Refract Surg 2006;32:1775-6 (Pubitemid 44436852)
17. Gunaydin I, Terhorst T, Eckstein A, et al. Assessment of keratoconjunctivitis sicca in patients with fibromyalgia: results of a prospective study. Rheumatol Int 1999;19(1-2):7-9 (Pubitemid 30025678)
18. Jeppesen KV, Fledelius HC . Femoxetine and eye function. A study of possible anticholinergic side effects. Pharmacopsychiatry 1985;18:231-4 (Pubitemid 15035483)
19. Ousler GW, Wilcox KA, Gupta G, Abelson MB. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004;93:460-4 (Pubitemid 39507713)
20. Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007;29:611-6 (Pubitemid 47016634)
21. Mah FS, O'Brien T, Kim T, Torkildsen G. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr Med Res Opin 2008;24:441-7 (Pubitemid 351294393)
22. Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, et al. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 2005;59:588-92 (Pubitemid 40632250)
23. Garely AD, Kaufman JM, Sand PK, et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006;28:1935-46 (Pubitemid 46043507)
24. Arango Toro O, Nohales Taurines G, Cortadellas Angel R, et al. [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder]. Actas Urol Esp 1998;22:124-30. Spanish
25. Fones CS, Kua EH, Ng TP, Ko SM. Studying the mental health of a nation: a preliminary report on a population survey in Singapore. Singapore Med J 1998;39:251-5 (Pubitemid 128519046)
26. Kua EH. A community study of mental disorders in elderly Singaporean Chinese using the GMS-AGECA T package. Aust N Z J Psychiatry 1992;26:502-6
27. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998;159:1245-52 (Pubitemid 28554501)
28. Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: a metaanalysis. Can J Psychiatry 1996;41:613-6 (Pubitemid 27062617)
29. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36 (Pubitemid 30173208)
30. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306(6879):683-7 (Pubitemid 23070230)
31. Remick RA . Anticholinergic side effects of tricyclic antidepressants and their management. Prog Neuropsychopharmacol Biol Psychiatry 1988;12(2-3):225-31
32. Ghaffariyeh A, Chamacham T. Tricyclic antidepressants: potential therapeutic alternatives for treatment of dry eye symptoms after LA SIK. J Refract Surg 2008;24:770-1; author reply 771-2
33. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004;19:754-62 (Pubitemid 39149252)
34. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm 1995;52:2799-812
35. Cipriani A, Brambilla P, Furukawa T, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005 Oct 19;(4):CD004185. Available from: http://www.mrw.interscience.wiley.com/cochrane/ clsysrev/articles/CD004185/frame.html
36. Cipriani A, Santilli C, Furukawa Toshi A, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009 Apr 15;(2):CD006532. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006532/ frame.html.
37. Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other antidepressive agents for depression. Cochrane Database of Syst Rev 2010;(3): CD006114. Available from: http://www.mrw.interscience.wiley.com/cochrane/ clsysrev/articles/CD006114/frame.html
38. Piek E, van der Meer K, Nolen WA. Guideline recommendations for longterm treatment of depression with antidepressants in primary care - a critical review. Eur J Gen Pract 2010;16:106-12
39. Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725-33
40. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-96 (Pubitemid 351989984)
41. Hunot VM, Horne R, Leese MN, Churchill RC. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry 2007;9:91-9 (Pubitemid 46607462)
42. Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010;(4):CD00611. Available from: http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD006117/frame.html
43. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993;13(6 Suppl 2):34S-9S (Pubitemid 24025200)
44. Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf 2008;31:109-26 (Pubitemid 351158523)
45. Blazer DG 2nd, Federspiel CF, Ray WA, Schaffner W. The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 1983;38:31-5 (Pubitemid 13217827)
46. Schein OD, Tielsch JM, Munoz B, et al. Relation between signs and symptoms of dry eye in the elderly. A population-based perspective. Ophthalmology 1997;104:1395-401 (Pubitemid 28116804)
47. Galor A, Feuer W, Lee DJ, et al. Prevalence and risk factors of dry eye syndrome in a United States Veterans Affairs population. Am J Ophthalmol 2011 Jun 17. Epub ahead of print
48. Gerlach J. [Clozepine (Leponex)]. Ugeskr Laeger 1984;146:3943-4. Danish
49. Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr 2005;17:227-33
50. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
51. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 2004;6(Suppl 2):20-3
52. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;(2):CD000967. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000967/frame. html
53. Ozbilen M, Adams CE . Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol 2009;29:141-6
54. Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2006;(2):CD005237. Available from: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005237/frame. html
55. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CA TIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31 (Pubitemid 36871054)
56. Tracy JI, Monaco CA, Abraham G, et al. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry 1998;59:184-8 (Pubitemid 28208333)
57. Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. Auton Neurosci 2007;30;133:3-18 (Pubitemid 46483257)
58. Gilbody S, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000;(3):CD002306. Available from: http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD002306/frame.html
59. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;(3):CD006654. Available from: http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD006654/frame.html
60. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;(1): CD006625. Available from: http://www.mrw.interscience.wiley.com/cochrane/ clsysrev/articles/CD006625/frame.html
61. Tan LC, Venketasubramanian N, Hong CY, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 2004;62:1999-2004 (Pubitemid 38738211)
62. Boiko AN, Batysheva TT, Chikina ES, et al. [Use of tremonorm in treatment of Parkinson's disease: outpatient experience of Moscow Municipal Health Care Service]. Zh Nevrol Psikhiatr Im S S Korsakova 2004;104:23-8. Russian
63. Illarioshkin SN, Ivanova-Smolenskaia IA, Zagorovskaia TB, et al. [7-year experience in usage of mirapex in patients with different forms of primary parkinsonism]. Zh Nevrol Psikhiatr Im S S Korsakova 2006;106:26-32. Russian
64. Levin OS, Boiko AN, Nesterova OS, et al. [Effect of dopamine agonist pramipexole (mirapex) on tremor, affective disorders and quality of life in patients with Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2010;110:39-44. Russian
65. Walzholz U. [Management of Parkinson's syndrome using levadopa. Results of a long-term study]. Dtsch Med Wochenschr 1972;28;97:686 passim. German
66. Goff DC, Arana GW, Greenblatt DJ, et al. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991;11:106-12
67. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2002;(3):CD003735. Available from: http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD003735/frame.html.
68. Armstrong RA . Visual signs and symptoms of Parkinson's disease. Clin Exp Optom 2008;91:129-38
69. Nishtala PS, Fois RA, McLachlan AJ, et al. Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. J Clin Pharmacol 2009;49:1176-84
70. Woodwell DA, Cherry DK. National Ambulatory Medical Care Survey: 2002 summary. Adv Data 2004;26(346):1-44
71. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:116-34 (Pubitemid 30106016)
72. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2011 Jul 22. [Epub ahead of print]
73. MOH clinical practice guidelines 2010. Available from: http://www.moh.gov.sg/mohcorp/uploadedFiles/Publications/Guidelines/ Clinical-Practice-Guidelines/Rhinosinusitis%20card%20.pdf
74. Bielory L. Ocular toxicity of systemic asthma and allergy treatments. Curr Allergy Asthma Rep 2006;6:299-305 (Pubitemid 44056826)
75. Welch D, Ousler GW 3rd, Nally LA, et al. Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect. Adv Exp Med Biol 2002;506(Pt B):1051-5
76. Hagan S, Lory B. Prevalence of dry eye among computer users. Optom Vis Sci 1998;75:712-3 (Pubitemid 28482104)
77. Goetz DW, Jacobson JM, Murnane JE, et al. Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine. J Allergy Clin Immunol 1989;84:316-22 (Pubitemid 19243972)
78. American Academy of Ophthalmology. Dry Eye Syndrome. Preferred Practice Pattern. San Francisco, CA, 2008
79. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-28 (Pubitemid 40139383)
80. Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005;5:8
81. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs 2001;61:2231-40; discussion 41-2.
82. Goetz DW, Jacobson JM, Apaliski SJ, et al. Objective antihistamine side effects are mitigated by evening dosing of hydroxyzine. Ann Allergy 1991;67:448-54
83. Hay-Smith J, Ellis G, Herbison GP. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;(3):CD005429. Available from: http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD005429/frame.html
84. Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2007;(4):CD003190. Available from: http://www.mrw.interscience.wiley.com/ cochrane/clsysrev/articles/CD003190/frame.html
85. Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults (Review). Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781
86. Halaska M, Madersbacher H, Voigt R, et al. Propiverine in patients with urgency and urge incontinence - a placebo controlled, multicenter study comparing its tolerability and efficacy with oxybutynin. International Urogynaecology Journal and Pelvic Floor Dysfunction. 2000;11(Suppl 1):46
87. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. Journal of Urology. 1991;145(April):813-7
88. Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008;102:1128-32
89. Vardy MD, Mitcheson HD, Samuels TA, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRA NT - a double-blind, placebo-controlled trial. Int J Clin Pract. 2009 Dec;63(12):1702-14.
90. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285-91 (Pubitemid 44838909)
91. Simon B, Reinicke HG, Dammann HG, Muller P. [3 mg telenzepine nocte in the treatment of benign stomach ulcer disease: a double-blind comparative study with 300 mg ranitidine nocte]. Z Gastroenterol 1990;28:90-3. German
92. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984;4:125-9 (Pubitemid 14051611)
93. Conti L, Pinder RM. A controlled comparative trial of mianserin and diazepam in the treatment of anxiety states in psychiatric out-patients. J Int Med Res 1979;7:285-9 (Pubitemid 9237061)
94. Halas CJ. Eszopiclone. Am J Health Syst Pharm 2006;63:41-8
95. Monti JM, Pandi-Perumal S. Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat 2007;3:441-53 (Pubitemid 350028009)
96. Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med 2008;102:32-41 (Pubitemid 350161846)
97. Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005;27:655-65 (Pubitemid 41439741)
98. Ingram JR, Grindlay DJ, Williams HC . Management of acne vulgaris: an evidence-based update. Clin Exp Dermatol 2010;35:351-4
99. Rigopoulos D, Larios G, Katsambas AD. The role of isotretinoin in acne therapy: why not as first-line therapy? Facts and controversies. Clin Dermatol 2010;28:24-30
100. Perry MD, McEvoy GK. Isotretinoin: new therapy for severe acne. Clin Pharm 1983;2:12-9 (Pubitemid 13181541)
101. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008;27:197-206
102. Caffery BE, Josephson JE. Ocular side effects of isotretinoin therapy. J Am Optom Assoc 1988;59:221-4
103. Egger SF, Huber-Spitzy V, Bohler K, Scholda C. [Isotretinoin administration in treatment of acne vulgaris. A prospective study of the kind and extent of ocular complications]. Ophthalmologe 1995;92:17-20
104. Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991;10:286-90
105. Lambert RW, Smith RE . Pathogenesis of blepharoconjunctivitis complicating 13-cis-retinoic acid (isotretinoin) therapy in a laboratory model. Invest Ophthalmol Vis Sci 1988;29:1559-64
106. Rismondo V, Ubels JL. Isotretinoin in lacrimal gland fluid and tears. Arch Ophthalmol 1987;105:416-20 (Pubitemid 17023312)
107. Rismondo V, Ubels JL, Osgood TB. Tear secretion and lacrimal gland function of rabbits treated with isotretinoin. J Am Acad Dermatol 1988;19(2 Pt 1):280-5
108. Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985;100:534-7 (Pubitemid 16206982)
109. Cumurcu T, Sezer E, Kilic R, Bulut Y. Comparison of dose-related ocular side effects during systemic isotretinoin administration. Eur J Ophthalmol 2009;19:196-200
110. Goulden V, Layton AM, Cunliffe WJ. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol 1994;131:360-3 (Pubitemid 24290220)
111. Kligman A. Topical tretinoin: indications, safety, and effectiveness. Cutis 1987;39:486-8 (Pubitemid 17089139)
112. Thielitz A, Abdel-Naser MB, Fluhr JW, et al. [Topical retinoids in acne - an evidence-based overview]. J Dtsch Dermatol Ges 2010;8 Suppl 1:S15-23. German
113. Aragona P, Cannavo SP, Borgia F, Guarneri F. Utility of studying the ocular surface in patients with acne vulgaris treated with oral isotretinoin: a randomized controlled trial. Br J Dermatol 2005;152:576-8 (Pubitemid 40547141)
114. Maino DM, Tran S, Mehta F. Side effects of chemotherapeutic oculo-toxic agents: a review. Clin Eye Vis Care 2000;12(3-4):113-7 (Pubitemid 32008591)
115. Doroshow JH, Locker GY, Gaasterland DE, et al. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer 1981;48:2158-62 (Pubitemid 12231584)
116. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007;30(4 Suppl 1):S10-6 (Pubitemid 47196597)
117. Aurich-Barrera B, Wilton L, Harris S, Shakir SA. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. Drug Saf 2006;29:151-60 (Pubitemid 43213888)
118. Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994;7(4 Pt 1):329-39 (Pubitemid 24138018)
119. Mackie IA, Seal DV, Pescod JM. Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction. Br J Ophthalmol 1977;61:354-9 (Pubitemid 8130844)
120. Jaanus SD. Ocular side effects of selected systemic drugs. Optom Clin 1992;2:73-96
121. Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care 2006;23:229-35
122. Teichman S. The anticholinergic side effects of disopyramide and controlled-release disopyramide. Angiology 1985;36:767-71 (Pubitemid 16235835)
123. Jonason T, Ringqvist I, Bandh S, et al. Propafenone versus disopyramide for treatment of chronic symptomatic ventricular arrhythmias. A multicenter study. Acta Med Scand 1988;223:515-23
124. Zacny JP, Lichtor JL, Flemming D, et al. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. J Pharmacol Exp Ther 1994;268:1-9. (Pubitemid 24039060)
125. Dias AC, Modulo CM, Jorge AG, et al. Influence of thyroid hormone on thyroid hormone receptor beta-1 expression and lacrimal gland and ocular surface morphology. Invest Ophthalmol Vis Sci 2007;48:3038-42 (Pubitemid 351261145)
126. Somps CJ, Greene N, Render JA, et al. A current practice for predicting ocular toxicity of systemically delivered drugs. Cutan Ocul Toxicol 2009;28:1-18